Secondary Cancer News and Research

RSS

Annual follow up after ESD for early gastric cancer recommended

Almost all recurrent lesions in gastric epithelial cancer could be cured by endoscopic submucosal resection with annual follow-up exams, say the authors of a Japanese study.

23 Aug 2012

High-risk HPV may increase chances of second malignancy in oral cancer

The proportion of oral squamous cell carcinoma patients infected with the human papillomavirus could be around a third, with high-risk versions of the virus accounting for almost three-quarters of those affected, indicate Taiwanese study results.

12 Jul 2012

Secreted vesicles play role in spread of cancer

Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called "soil and seed" theory of 1889. New details that could help shed light on this hypothesis have been provided by a team of researchers from Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, proposing a new mechanism controlling cancer metastasis that offers fresh diagnostic and treatment potential.

29 May 2012

Secondary cancer risk from MDCT scans is low among older adults

The secondary cancer risk from multi-detector computed tomography (MDCT) scans is low among older adults, according to a study from Stanford University in the April issue of the Journal of the American College of Radiology. MDCT is a high-speed imaging technique that is commonly used to diagnose a variety of diseases and conditions.

3 Apr 2012

Papillary renal cell carcinoma patients face low tumour re-occurrence and cancer-related death rates

Patients with papillary renal cell carcinoma, the second most common kidney cancer subtype, face a low risk of tumour recurrence and cancer-related death after surgery. Those are the key findings of a multi-centre study of nearly 600 patients published in the April issue of the urology journal BJUI.

29 Mar 2012

New technique can detect small secondary brain tumours

Cancer Research UK scientists have developed a technique they believe could be used to detect tiny secondary tumours in the brain, a process that is currently impossible, according to research published in PNAS.

27 Mar 2012

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

Additional pathology tests can improve survival rates in patients with oesophageal cancer

A University of Adelaide medical researcher says current treatment for people diagnosed with oesophageal cancer could be improved with additional pathology tests.

2 Mar 2011

Study: Genetic variations in miRNA pathway may be used to predict secondary tumor in head and neck cancer patients

Eighteen single-point genetic variations indicate risk of recurrence for early-stage head and neck cancer patients and their likelihood of developing a second type of cancer, researchers at The University of Texas M. D. Anderson Cancer Center reported at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference.

8 Dec 2009

Testicular cancer survivors at risk of effective treatment

Testicular cancer survivors can face an increased risk of long-term illness, not because of the malignancy, but the highly effective treatment they receive, according to a study in the urology journal BJUI.

20 Oct 2009

BJUI: Testicular cancer survivors face an increased risk of long-term illness due to effective treatment

19 Oct 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009